1. van der Valk R' Webers CA' Schouten JS' et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177-1185.

2. Eisenberg DL' Toris CB' Camras CB. Bimatoprost and travoprost. a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47(suppl 1):S105-S115.

3. Netland PA' Landry T' Sullivan EK' et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Oph-thalmol. 2001;132:472-484.

4. Sherwood M' Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(suppl 2):S361-S368.

5. Camras CB' Toris CB' Sjoquist B' et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery. Ophthalmology. 2004;111:2193-2198.

6. Crowston JG' Lindsey JD' Morris CA' et al. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci. 2005;46:4571-4577.

7. Ota T' Aihara M' Narumiya S' Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005;46: 4159-4163.

Susanna R, Jr., Chew P, Kitazawa Y. Current status of prostaglandin therapy: lata-noprost and unoprostone. Surv Ophthalmol. 2002;47(suppl 1):S97-S104. Jampel HD, Bacharach J, Sheu WP, et al. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol. 2002; 134:863-871.

Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci. 1977;16: 1125-1134.

Weinreb R, Toris C, Gabelt B, et al. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002;47(suppl 1):S53-S64. Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous pros-taglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol. 1997;41(suppl 2):S69-S75.

Toris CB, Zhan G, Camras CB. Increase in outflow facility with unoprostone treatment in ocular hypertensive patients. Arch Ophthalmol. 2004;122:1782-1787. Christiansen GA, Nau CB, McLaren JW, Johnson DH. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004;111:1658-1662.

Toris CB, Alm A, Camras CB. Latanoprost and cholinergic agonists in combination. Surv Ophthalmol. 2002;47(suppl 1):S141-S147.

Dinslage S, Hueber A, Diestelhorst M, Krieglstein G. The influence of latanoprost 0.005% on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study. Graefes Arch Clin Exp Ophthalmol. 2004; 242:654-660.

Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology. 1999;106:550-555.

Marchini G, Ghilotti G, Bonadimani M, Babighian S. Effects of 0.005% latanoprost on ocular anterior structures and ciliary body thickness. J Glaucoma. 2003;12:295-300. Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci. 2002;43:716-722. Camras CB, Friedman AH, Rodrigues MM, et al. Multiple dosing of prostaglandin F2a or epinephrine on cynomolgus monkey eyes. III. Histopathology. Invest Ophthalmol Vis Sci. 1988;29:1428-1436.

Tomita G, Araie M, Kitazawa Y, Tsukahara S. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye. 2004;18:984-989.

Hoyng PF, Kitazawa Y. Medical treatment of normal tension glaucoma. Surv Ophthalmol. 2002;47(suppl 1):S116-S124.

Ang A, Reddy MA, Shepstone L, Broadway DC. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol. 2004;88:630-634. Liu CJ, Ko YC, Cheng CY, et al. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. Ophthalmology. 2002;109:2241-2247.

Konstas AG, Mylopoulos N, Karabatsas CH, et al. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye. 2004;18:893-899. Nordmann JP, Mertz B, Yannoulis NC, et al. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol. 2002;133:1-10. Camras CB, Alm A, Watson PG, et al. Latanoprost, a prostaglandin analog, for glaucoma therapy: efficacy and safety after one year of treatment in 198 patients. Ophthalmology. 1996;103:1916-1924.

Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122:957-965.

Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology. 1995;102:1743-1752. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41(suppl 2):S105-S110.

Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol. 2002;47(suppl 1):S65-S76. Sakai H, Shinjyo S, Nakamura Y, et al. Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients. J Ocul Pharmacol Ther. 2005;21:483-489.

Chew PT, Aung T, Aquino MV, Rojanapongpun P. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma. Ophthalmology. 2004;111:427-434.

Sihota R, Saxena R, Agarwal HC, Gulati V. Crossover comparison of timolol and latanoprost in chronic primary angle-closure glaucoma. Arch Ophthalmol. 2004;122: 185-189.

Chew PT, Hung PT, Aung T. Efficacy of latanoprost in reducing intraocular pressure in patients with primary angle-closure glaucoma. Surv Ophthalmol. 2002;47(suppl 1): S125-S128.

Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47(suppl 1):S219-S230.

Enyedi LB, Freedman SF. Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol. 2002;47(suppl 1):S129-S132.

Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of lata-noprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology. 2006;113:239-246. Larsson L-I, Mishima HK, Takamatsu M, et al. The effect of latanoprost on circadian intraocular pressure. Surv Ophthalmol. 2002;47(suppl 1):S90-S96. Choi J, Jeong J, Cho HS, Kook MS. Effect of nocturnal blood pressure reduction on circadian fluctuation of mean ocular perfusion pressure: a risk factor for normal tension glaucoma. Invest Ophthalmol Vis Sci. 2006;47:831-836. Arici MK, Erdogan H, Toker I, et al. The effect of latanoprost, bimatoprost, and travoprost on intraocular pressure after cataract surgery. J Ocul Pharmacol Ther. 2006; 22:34-40.

Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123:186-192.

Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol. 2002;133:393-397.

Cohen JS, Gross RL, Cheetham JK, et al. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49(suppl 1):S45-S52.

Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003; 135:688-703.

Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63. Camras CB; the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147. Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286-1293.

Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and

0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology. 2002;109:998-1008.

Stjernschantz J, Albert D, Hu D, et al. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47(suppl 1):S162-

Reducing Blood Pressure Naturally

Reducing Blood Pressure Naturally

Do You Suffer From High Blood Pressure? Do You Feel Like This Silent Killer Might Be Stalking You? Have you been diagnosed or pre-hypertension and hypertension? Then JOIN THE CROWD Nearly 1 in 3 adults in the United States suffer from High Blood Pressure and only 1 in 3 adults are actually aware that they have it.

Get My Free Ebook

Post a comment